TY - JOUR
T1 - Clinical pharmacokinetics of cyclophosphamide
AU - De Jonge, Milly E.
AU - Huitema, Alwin D.R.
AU - Rodenhuis, Sjoerd
AU - Beijnen, Jos H.
N1 - Funding Information:
This work was supported by a grant from the Dutch Cancer Society (project NKI 2001-2420). The authors have no conflicts of interest that are directly relevant to the content of this review.
PY - 2005
Y1 - 2005
N2 - Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of the clinical pharmacology of this drug. As these techniques are becoming increasingly available, adequate description of the pharmacokinetics of cyclophosphamide and its metabolites has become possible. There is incomplete understanding on the role of cyclophosphamide metabolites in the efficacy and toxicity of cyclophosphamide therapy. However, relationships between toxicity (cardiotoxicity, veno-occlusive disease) and exposure to cyclophosphamide and its metabolites have been established. Variations in the balance between metabolic activation and inactivation of cyclophosphamide owing to autoinduction, dose escalation, drug-drug interactions and individual differences have been reported, suggesting possibilities for optimisation of cyclophosphamide therapy. Knowledge of the pharmacokinetics of cyclophosphamide, and possibly monitoring the pharmacokinetics of cyclophosphamide in individuals, may be useful for improving its therapeutic index.
AB - Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of the clinical pharmacology of this drug. As these techniques are becoming increasingly available, adequate description of the pharmacokinetics of cyclophosphamide and its metabolites has become possible. There is incomplete understanding on the role of cyclophosphamide metabolites in the efficacy and toxicity of cyclophosphamide therapy. However, relationships between toxicity (cardiotoxicity, veno-occlusive disease) and exposure to cyclophosphamide and its metabolites have been established. Variations in the balance between metabolic activation and inactivation of cyclophosphamide owing to autoinduction, dose escalation, drug-drug interactions and individual differences have been reported, suggesting possibilities for optimisation of cyclophosphamide therapy. Knowledge of the pharmacokinetics of cyclophosphamide, and possibly monitoring the pharmacokinetics of cyclophosphamide in individuals, may be useful for improving its therapeutic index.
UR - http://www.scopus.com/inward/record.url?scp=26944481572&partnerID=8YFLogxK
U2 - 10.2165/00003088-200544110-00003
DO - 10.2165/00003088-200544110-00003
M3 - Review article
C2 - 16231966
AN - SCOPUS:26944481572
SN - 0312-5963
VL - 44
SP - 1135
EP - 1164
JO - Clinical Pharmacokinetics
JF - Clinical Pharmacokinetics
IS - 11
ER -